Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib
Enliven Therapeutics has announced alignment with the FDA on the design for its ENABLE-2 Phase 3 trial evaluating relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia.